127799-53-5

Usage

Uses

Used in Pharmaceutical Industry:
1-(benzyloxy)carbonyl-2-(t-butyloxy)carbonyl-1-Methylhydrazine is utilized as a key building block in the synthesis of various pharmaceuticals. Its unique structure allows for the development of potential drug candidates with specific therapeutic properties. The benzyl and t-butyl groups contribute to the compound's reactivity, enabling the formation of new chemical entities with desired pharmacological activities.
Used in Agrochemical Industry:
In the agrochemical sector, 1-(benzyloxy)carbonyl-2-(t-butyloxy)carbonyl-1-Methylhydrazine serves as an essential component in the creation of novel agrochemicals. Its structural attributes make it a valuable precursor in the synthesis of compounds with pesticidal, herbicidal, or other agricultural applications. 1-(benzylo×y)carbonyl-2-(t-butylo×y)carbonyl-1-Methylhydrazine's versatility in organic synthesis facilitates the development of innovative agrochemicals to address various agricultural challenges.
Used in Chemical Synthesis:
1-(benzyloxy)carbonyl-2-(t-butyloxy)carbonyl-1-Methylhydrazine is employed as an intermediate in various chemical reactions, allowing for the formation of a wide range of organic compounds. Its presence in the molecule can influence the reactivity and stability of the resulting products, making it a crucial component in the synthesis of new materials and chemical entities.
Used in Drug Discovery:
Researchers actively explore the potential applications of 1-(benzyloxy)carbonyl-2-(t-butyloxy)carbonyl-1-Methylhydrazine in drug discovery. Its unique structural features and reactivity make it a promising candidate for the development of new therapeutic agents. 1-(benzylo×y)carbonyl-2-(t-butylo×y)carbonyl-1-Methylhydrazine's versatility in organic synthesis enables the creation of diverse drug candidates with potential applications in various medical fields.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 37519-04-3 1-(benzyloxy)carbonyl-1-methylhydrazine 
• 185456-32-0 1-benzyl-1,2,2-tris(tert-butoxycarbonyl)hydrazine 
• 426840-24-6 N^α-(benzyloxycarbonyl)-N^β,N^β-bis(tert-butyloxycarbonyl)-N^α-methylhydrazine 
• 5331-43-1 N-benzyloxycarbonyl-hydrazine 
• 200813-53-2 1-tert-butoxycarbonyl-1-tosyl-2-benzyloxycarbonylhydrazine 
• 200813-52-1 benzyl 2-tosylhydrazine-1-carboxylate 
• 287729-00-4 N-benzyl-N-tert-butyloxycarbonylaminophthalimide 
• 287729-06-0 N-methyl-N-benzyloxycarbonylaminophthalimide 
• 287728-91-0 N-benzyloxycarbonylaminophthalimide 
• 200813-54-3 2-benzyloxycarbonyl-1-tert-butoxycarbonyl-2-methyl-1-(4-methylphenylsulfonyl)hydrazine 

Downstream Products

• 151988-40-8 (S)-2-(N'-tert-Butoxycarbonyl-N-methyl-hydrazinocarbonyl)-pyrrolidine-1-carboxylic acid benzyl ester 
• 220079-44-7 1-(benzyloxycarbonyl)-2-ethyl-1-methyl-2-[(trideuteromethyl)tosylcarbamoyl]hydrazine 
• 220079-71-0 N'-[Benzyl-(toluene-4-sulfonyl)-aminocarbonyl]-N-ethyl-N'-methyl-hydrazinecarboxylic acid tert-butyl ester 
• 220079-41-4 N'-Ethyl-N-methyl-N'-(toluene-4-sulfonylaminocarbonyl)-hydrazinecarboxylic acid benzyl ester 
• 220079-68-5 N-Ethyl-N'-methyl-N'-(toluene-4-sulfonylaminocarbonyl)-hydrazinecarboxylic acid tert-butyl ester 
• 220079-20-9 N'-Ethyl-N'-(4-fluoro-benzoyl)-N-methyl-hydrazinecarboxylic acid benzyl ester 
• 220079-16-3 N'-Ethyl-N-methyl-hydrazinecarboxylic acid benzyl ester 
• 220079-14-1 1-(benzyloxycarbonyl)-2-(tert-butoxycarbonyl)-2-ethyl-1-methylhydrazine 
• 127799-54-6 2-Methylhydrazinecarboxylic acid,1,1-dimethylethyl ester 

Relevant academic research and scientific papers

FACTOR XIA-INHIBITING PYRIDOBENZAZEPINE AND PYRIDOBENZAZOCINE DERIVATIVES

The invention relates to substituted pyridobenzazepine and pyridobenzazocine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

Preparation of Multiply Protected Alkylhydrazine Derivatives by Mitsunobu and PTC Approaches

Alkylation reactions of hydrazine derivatives by Mitsunobu or PTC approaches are described. It has been shown that aminophthalimide derivatives are better acidic partners than their aminoimidodicarbonate (NBoc2) analogues, the presence of the phthaloyl group increasing the acidity of the sole proton and concomitantly reducing steric hindrance. Moreover, N-aminophthalimide derivatives can be efficiently converted into the corresponding N-amino-imidodicarbonates by a three-stage, one-flask procedure under very mild conditions. These procedures can also be efficiently used for the preparation of orthogonally Nα,Nβ -diprotected α-hydrazino esters. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003).

Very efficient one-pot conversion of N-aminophthalimide derivatives into the corresponding N-amino-di-tert-butyl imidodicarbonates

The phthaloyl group can be efficiently converted in very mild conditions into bis-tert-butyloxycarbonyl group using MeNH2, then Boc2O/DMAP, in a one-flask protocol.

A practical reagent for the synthesis of substituted hydrazines

A practical, inexpensive triprotected hydrazine reagent, 2-benzyloxycarbonyl-1 -tert-butoxycarbonyl-1- (4-methylphenylsulfonyl)-hydrazine, 1-Boc-1-Tos-2-Z-hydrazine (2), has been prepared on a 100 pnmol scale and examined with respect to application in st

Synthesis of fused 1,2,5-triazepine-1,5-diones and some N2- and N3-substituted derivatives: Potential conformational mimetics for cis-peptidyl prolinamides

The synthesis of a new fused 1,2,5-triazepine-1,5-dione heterocycle, which is expected to mimic structural features of cis-peptldyl prolinamides, is described. The required parent heterocycle, corresponding to cis-glycy-(2S)-prolinamide, has been prepared in good yield by the cyclisation of N-(2-bromoacetylprolyl)-hydrazine which is itself generated in situ from the bromoacetyl proline methyl ester. Analogues corresponding to cis-(2R)-alanyl- and cis-(2S)-alanyl-(2S)-prolinamide have been similarly prepared from the appropriate N-(2-bromopropionyl)proline methyl esters and hydrazine hydrate where the cyclisation step, involving the displacement of bromide, has been shown to occur with inversion of configuration at C-2 of the propionyl moiety. Acylation at the N-3 position of the triazepine is equivalent to N-terminal acylation of the residue preceding the proline residue in cis-aminoacyl prolinamides. This has been achieved without incident using standard peptide coupling procedures. Extension at the 'C-terminal' has been achieved by preparing elaborated hydrazine precursors which are reacted with suitably activated esters of N-α-halogenoacylprolines, prior to cyclisation, to give the required fused triazepine dione. Thus it is possible to prepare constrained cis-peptidyl prolyl peptide mimetics of defined stereochemistry based upon this new triazepine dione in which all of the non-proline residues can be varied.

Synthesis and structure of AzAsx-pro-containing Aza-peptides

One possible α-modification in peptides is the substitution of a nitrogen for the CαH group. We propose triphosgene as a carbonylating agent for coupling the properly substituted hydrazide to the proline nitrogen to obtain the AzAsx-Pro or AzAl

Conformational perturbations induced by N-amination and N-hydroxylation of peptides

Amination and bydroxylation of the amide nitrogen in a peptide chain have little influence on the local geometry, but both affect the hydrogen-bonding network, and therefore the conformational properties of the modified peptide. An experimental study in solution (IR spectroscopy and 1H-NMR) and in the solid state (X-ray diffraction) has been carried out on the N-amino and N-hydroxy analogues of the two RCO-Pro-NHMe and RCO-Pro-Gly-NHiPr peptides known to adopt preferentially the γ- and β-turn structures, respectively. The N-amino group is a weak proton donor which does not interact significantly with the peptide chain. On the contrary, the N-hydroxyl group is a strong proton donor giving close contacts with the peptide carbonyls. The resulting folded conformers of an expanded γ- or β-like type, presenting an 8- or 11-membered cycle instead of a 7- or 10-membered cycle in the cognate peptides have been also analyzed by a SYBYL molecular dynamics simulation.

MONOBACTAM HYDRAZIDES CONTAINING CATECHOL SULFONIC ACID GROUPS

Antibacterial activity is exhibited by novel compounds having the formula or a pharmaceutically acceptable salt thereof. R3 and R4 are the same or different and each is hydrogen or alkyl or R3 and R4 taken together with the nitrogen atoms to which they are attached form a 1,2-diazacyclobutane, 1,2-diazacyclopentane, 1,2-diazacyclohexane, or 1,2-diazacycloheptane ring. Y1 and Y2 are either hydrogen or OR11 but are not the same. R11 is hydrogen, alkanoyl of from one to ten carbon atoms, substituted alkanoyl of from two to ten carbon atoms, phenylcarbonyl, (substituted phenyl) carbonyl, heteroarylcarbonyl, phenylalkanoyl, (substituted phenyl) alkanoyl, or heteroarylalkanoyl